These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 9399218)
1. Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets. Smith LA; Gordin A; Jenner P; Marsden CD Mov Disord; 1997 Nov; 12(6):935-45. PubMed ID: 9399218 [TBL] [Abstract][Full Text] [Related]
2. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure. Smith LA; Jackson MJ; Hansard MJ; Maratos E; Jenner P Mov Disord; 2003 May; 18(5):487-95. PubMed ID: 12722161 [TBL] [Abstract][Full Text] [Related]
3. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Smith LA; Jackson MJ; Al-Barghouthy G; Rose S; Kuoppamaki M; Olanow W; Jenner P Mov Disord; 2005 Mar; 20(3):306-14. PubMed ID: 15490461 [TBL] [Abstract][Full Text] [Related]
4. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset. Tayarani-Binazir KA; Jackson MJ; Fisher R; Zoubiane G; Rose S; Jenner P Eur J Pharmacol; 2010 Jun; 635(1-3):109-16. PubMed ID: 20303948 [TBL] [Abstract][Full Text] [Related]
5. The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates. Zubair M; Jackson MJ; Tayarani-Binazir K; Stockwell KA; Smith LA; Rose S; Olanow W; Jenner P Exp Neurol; 2007 Dec; 208(2):177-84. PubMed ID: 17935716 [TBL] [Abstract][Full Text] [Related]
6. The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets. Tayarani-Binazir K; Jackson MJ; Rose S; McCreary AC; Jenner P Exp Neurol; 2010 Dec; 226(2):320-7. PubMed ID: 20843474 [TBL] [Abstract][Full Text] [Related]
7. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets. Rose S; Jackson MJ; Smith LA; Stockwell K; Johnson L; Carminati P; Jenner P Eur J Pharmacol; 2006 Sep; 546(1-3):82-7. PubMed ID: 16925991 [TBL] [Abstract][Full Text] [Related]
8. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates. Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355 [TBL] [Abstract][Full Text] [Related]
9. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993 [TBL] [Abstract][Full Text] [Related]
10. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Brooks DJ; Agid Y; Eggert K; Widner H; Ostergaard K; Holopainen A; Eur Neurol; 2005; 53(4):197-202. PubMed ID: 15970632 [TBL] [Abstract][Full Text] [Related]
11. [Inhibition of the COMPT with entacapone in the treatment of motor fluctuations in Parkinson disease]. Kulisevsky J Neurologia; 1999; 14(7):349-58. PubMed ID: 10570622 [TBL] [Abstract][Full Text] [Related]
12. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect. Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340 [TBL] [Abstract][Full Text] [Related]
13. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease. Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066 [TBL] [Abstract][Full Text] [Related]
14. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. Fung VS; Herawati L; Wan Y; ; Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551 [TBL] [Abstract][Full Text] [Related]
15. The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets. Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T Eur J Pharmacol; 2015 Jan; 747():160-5. PubMed ID: 25499739 [TBL] [Abstract][Full Text] [Related]
16. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638 [TBL] [Abstract][Full Text] [Related]
17. Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets. Tayarani-Binazir KA; Jackson MJ; Rose S; Olanow CW; Jenner P Mov Disord; 2010 Feb; 25(3):377-84. PubMed ID: 20108359 [TBL] [Abstract][Full Text] [Related]
18. The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets. Pearce RK; Smith LA; Jackson MJ; Banerji T; Scheel-Krüger J; Jenner P Mov Disord; 2002 Sep; 17(5):877-86. PubMed ID: 12360536 [TBL] [Abstract][Full Text] [Related]
19. The dopamine D(2) receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with L-dopa. Jackson MJ; Andree TH; Hansard M; Hoffman DC; Hurtt MR; Kehne JH; Pitler TA; Smith LA; Stack G; Jenner P J Neural Transm (Vienna); 2010 Jan; 117(1):55-67. PubMed ID: 19809864 [TBL] [Abstract][Full Text] [Related]